{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:49Z","timestamp":1756902169381,"version":"3.44.0"},"reference-count":109,"publisher":"The Pediatric Pharmacy Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Inborn errors of metabolism comprise a wide array of diseases and complications in the pediatric patient. The rarity of these disorders limits the ability to conduct and review robust literature regarding the disease states, mechanisms of dysfunction, treatments, and outcomes. Often, treatment plans will be based on the pathophysiology associated with the disorder and theoretical agents that may be involved in the metabolic process. Medication therapies usually consist of natural or herbal products. Established efficacious pediatric doses for these products are difficult to find in tertiary resources, and adverse effects are routinely limited to single case reports. This review article attempts to summarize some of the more common inborn errors of metabolism in a manner that is applicable to pharmacists who will provide care for these patients.<\/jats:p>","DOI":"10.5863\/1551-6776-23.6.432","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T17:04:17Z","timestamp":1547571857000},"page":"432-446","source":"Crossref","is-referenced-by-count":7,"title":["An Introduction to Pharmacotherapy for Inborn Errors of Metabolism"],"prefix":"10.5863","volume":"23","author":[{"given":"Aaron A.","family":"Harthan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"year":"2004","series-title":"A Clinical Guide to Inherited Metabolic Diseases","key":"i1551-6776-23-6-432-b1","unstructured":"Clarke\n              JTR.\n            \n          \n          A Clinical Guide to Inherited Metabolic Diseases. 2nd ed.Cambridge, United Kingdom: Cambridge University Press; 2004."},{"issue":"2","key":"i1551-6776-23-6-432-b2","series-title":"Am J Health Syst Pharm","first-page":"182","article-title":"Pediatric congenital errors of metabolism: the pharmacist's extended role","volume":"60","year":"2003","unstructured":"Cutts\n              C.\n            \n          \n          Pediatric congenital errors of metabolism: the pharmacist's extended role. Am J Health Syst Pharm. 2003;60(2):182\u2013184."},{"issue":"3","key":"i1551-6776-23-6-432-b3","series-title":"Indian J Clin Biochem","first-page":"215","article-title":"Inborn errors of metabolism: review and data from a tertiary care center","volume":"24","year":"2009","unstructured":"Rao\n              AN\n            , CavithaJ, KochM, \n          et al. Inborn errors of metabolism: review and data from a tertiary care center. Indian J Clin Biochem. 2009;24(3):215\u2013222."},{"issue":"9","key":"i1551-6776-23-6-432-b4","series-title":"Clin Chem","first-page":"1615","article-title":"National academy of clinical biochemistry laboratory medicine practice guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry; executive summary","volume":"55","year":"2009","unstructured":"Dietzen\n              DJ\n            , RinaldoP, WhitleyRJ, \n          et al. National academy of clinical biochemistry laboratory medicine practice guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry; executive summary. Clin Chem. 2009;55(9):1615\u20131626."},{"year":"2014","series-title":"Biochemistry: The Molecular Basis of Life","key":"i1551-6776-23-6-432-b5","unstructured":"Mckee\n              T\n            , McKeeJR.\n          Biochemistry: The Molecular Basis of Life. Oxford, United Kingdom: Oxford University Press; 2014."},{"issue":"6026","key":"i1551-6776-23-6-432-b6","series-title":"Br Med J","first-page":"41","article-title":"Letter: glucose is dextrose is glucose","volume":"2","year":"1976","unstructured":"Baron\n              DN\n            , McIntyreN.\n          Letter: glucose is dextrose is glucose. Br Med J. 1976;2(6026):41\u201342."},{"issue":"2","key":"i1551-6776-23-6-432-b7","series-title":"J Inherit Metab Dis","first-page":"105","article-title":"The biochemical basis of hereditary fructose intolerance","volume":"33","year":"2010","unstructured":"Bouteldja\n              N\n            , TimsonDJ.\n          The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis. 2010;33(2):105\u2013112."},{"issue":"4","key":"i1551-6776-23-6-432-b8","series-title":"Arch Dis Child","first-page":"413","article-title":"Iatrogenic deaths in hereditary fructose intolerance","volume":"69","year":"1993","unstructured":"Cox\n              TM.\n            \n          \n          Iatrogenic deaths in hereditary fructose intolerance. Arch Dis Child. 1993;69(4):413\u2013415."},{"issue":"7","key":"i1551-6776-23-6-432-b9","series-title":"J Am Diet Assoc","first-page":"1128","article-title":"Is medical nutrition therapy (MNT) the same for hereditary vs dietary fructose intolerance","volume":"110","year":"2010","unstructured":"Marcason\n              W.\n            \n          \n          Is medical nutrition therapy (MNT) the same for hereditary vs dietary fructose intolerance. J Am Diet Assoc. 2010;110(7):1128."},{"key":"i1551-6776-23-6-432-b10","series-title":"Nelson's Textbook of Pediatrics","article-title":"Defects in metabolism of carbohydrates","year":"2011","unstructured":"Kishnani\n              PS\n            , ChenYT.\n          Defects in metabolism of carbohydrates. In: KliegmanRM, StantonBF, St. GemeIIIJW, et al, eds.Nelson's Textbook of Pediatrics. 19th ed.Philadelphia, PA: Elsevier; 2011."},{"issue":"4","key":"i1551-6776-23-6-432-b11","series-title":"J Inherit Metab Dis","first-page":"516","article-title":"Classical galactosaemia revisited","volume":"29","year":"2006","unstructured":"Bosch\n              AM.\n            \n          \n          Classical galactosaemia revisited. J Inherit Metab Dis. 2006;29(4):516\u2013525."},{"issue":"5","key":"i1551-6776-23-6-432-b12","series-title":"Eur J Paediatr Neurol","first-page":"497","article-title":"Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation: case report and mini-review","volume":"19","year":"2015","unstructured":"Castiglioni\n              C\n            , VerrigniD, OkumaC, \n          et al. Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation: case report and mini-review. Eur J Paediatr Neurol. 2015;19(5):497\u2013503."},{"issue":"1","key":"i1551-6776-23-6-432-b13","series-title":"Semin Neonatol","first-page":"17","article-title":"Management and emergency treatments of neonates with a suspicion of inborn errors of metabolism","volume":"7","year":"2002","unstructured":"Ogier de Baulny\n              H.\n            \n          \n          Management and emergency treatments of neonates with a suspicion of inborn errors of metabolism. Semin Neonatol. 2002;7(1):17\u201326."},{"issue":"2","key":"i1551-6776-23-6-432-b14","series-title":"Dev Med Child Neurol","first-page":"e1","article-title":"Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis","volume":"52","year":"2010","unstructured":"Barnerias\n              C\n            , SaudubrayJM, TouatiG, \n          et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol. 2010;52(2):e1\u2013e9."},{"issue":"7","key":"i1551-6776-23-6-432-b15","series-title":"J Neurol Neurosurg Psychiatry","first-page":"846","article-title":"Thiamine responsive pyruvate dehydrogenase deficiency in an adult with peripheral neuropathy and optic neuropathy","volume":"79","year":"2008","unstructured":"Sedel\n              F\n            , ChalleG, MayerJM, \n          et al. Thiamine responsive pyruvate dehydrogenase deficiency in an adult with peripheral neuropathy and optic neuropathy. J Neurol Neurosurg Psychiatry. 2008; 79(7):846\u2013847."},{"key":"i1551-6776-23-6-432-b16","series-title":"BMJ Case Rep","article-title":"Angioneurotic oedema secondary to oral thiamine","volume":"2013","year":"2013","unstructured":"Osman\n              M\n            , CaseyP.\n          Angioneurotic oedema secondary to oral thiamine. BMJ Case Rep. 2013;2013: pii: bcr2013200558. DOI: 10.1136\/bcr-2013-200558."},{"key":"i1551-6776-23-6-432-b17","series-title":"Nelson's Textbook of Pediatrics","article-title":"Urea cycle and hyperammonemia (arginine, citrulline, ornithine)","year":"2011","unstructured":"Rezvani\n              I\n            , YudkoffM.\n          Urea cycle and hyperammonemia (arginine, citrulline, ornithine). In: KliegmanRM, StantonBF, St GemeJWIII, et al, eds.Nelson's Textbook of Pediatrics. 19th ed.Philadelphia, PA: Elsevier; 2011."},{"key":"i1551-6776-23-6-432-b18","series-title":"Orphanet J Rare Dis","first-page":"32","article-title":"Suggested guidelines for the diagnosis and management of urea cycle disorders","volume":"7","year":"2012","unstructured":"H\u00e4berle\n              J\n            , BoddaertN, BurlinaA, \n          et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32."},{"issue":"3","key":"i1551-6776-23-6-432-b19","series-title":"J Paediatr Child Health","first-page":"E96","article-title":"Arginine extravasation leading to skin necrosis","volume":"48","year":"2012","unstructured":"Abraham\n              MB\n            , van der WesthuyzenJ, KhannaV.\n          Arginine extravasation leading to skin necrosis. J Paediatr Child Health. 2012;48(3):E96\u2013E97."},{"issue":"6","key":"i1551-6776-23-6-432-b20","series-title":"PLoS One","first-page":"e2347","article-title":"Safety profile of L-arginine infusion in moderately severe falciparum malaria","volume":"3","year":"2008","unstructured":"Yeo\n              TW\n            , LampahDA, GitawatiR, \n          et al. Safety profile of L-arginine infusion in moderately severe falciparum malaria. PLoS One. 2008;3(6):e2347."},{"issue":"4","key":"i1551-6776-23-6-432-b21","series-title":"Pediatr Int","first-page":"506","article-title":"Diagnosis and treatment of urea cycle disorder in Japan","volume":"56","year":"2014","unstructured":"Nakamura\n              K\n            , KidoJ, MitsubuchiH, \n          et al. Diagnosis and treatment of urea cycle disorder in Japan. Pediatr Int. 2014;56(4):506\u2013509."},{"issue":"6","key":"i1551-6776-23-6-432-b22","series-title":"Arch Dis Child","first-page":"454","article-title":"Drug treatment of inborn errors of metabolism","volume":"98","year":"2013","unstructured":"Alfadhel\n              M\n            , Al-ThihilK, MoubayedH\n          et al. Drug treatment of inborn errors of metabolism. Arch Dis Child. 2013;98(6):454\u2013461."},{"issue":"5","key":"i1551-6776-23-6-432-b23","series-title":"Can Med Assoc J","first-page":"447","article-title":"Vitamin C for prophylaxis of tyrosinemia in the newborn","volume":"114","year":"1976","unstructured":"The nutrition committee of the Canadian Paediatric Society. \n          Vitamin C for prophylaxis of tyrosinemia in the newborn. Can Med Assoc J. 1976;114(5):447."},{"issue":"1","key":"i1551-6776-23-6-432-b24","series-title":"Adv Nutr","first-page":"16","article-title":"Vitamin C","volume":"5","year":"2014","unstructured":"Lykkesfeldt\n              J\n            , MichelsAJ, FreiB.\n          Vitamin C. Adv Nutr. 2014;5(1):16\u201318."},{"issue":"4","key":"i1551-6776-23-6-432-b25","series-title":"Urology","first-page":"922","article-title":"High-dose supplementation with vitamin C-induced pediatric urolithiasis: the first case report in a child and literature review","volume":"84","year":"2014","unstructured":"Chen\n              X\n            , ShenL, GuX, \n          et al. High-dose supplementation with vitamin C-induced pediatric urolithiasis: the first case report in a child and literature review. Urology. 2014;84(4):922\u2013924."},{"issue":"3","key":"i1551-6776-23-6-432-b26","series-title":"Am J Kidney Dis","first-page":"400","article-title":"Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones","volume":"67","year":"2016","unstructured":"Ferraro\n              PM\n            , CurhanGC, GambaroG, \n          et al. Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones. Am J Kidney Dis. 2016;67(3):400\u2013407."},{"key":"i1551-6776-23-6-432-b27","series-title":"GeneReviews","article-title":"Homocystinuria caused by cystathionine beta-synthase deficiency","year":"2017","unstructured":"Sacharow\n              SJ\n            , PickerJD, LevyHL.\n          Homocystinuria caused by cystathionine beta-synthase deficiency. In: PagonRA, AdamMP, ArdingerHH, et al, eds.GeneReviews. Seattle, WA: University of Washington; 2017."},{"issue":"2","key":"i1551-6776-23-6-432-b28","series-title":"Eur J Pediatr","first-page":"241","article-title":"Titration of betaine therapy to optimize therapy in an infant with 5,10-methylenetetrahydrofolate reductase deficiency","volume":"169","year":"2010","unstructured":"Ucar\n              SK\n            , KorogluOA, BerkO, \n          et al. Titration of betaine therapy to optimize therapy in an infant with 5,10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr. 2010;169(2):241\u2013243."},{"key":"i1551-6776-23-6-432-b29","series-title":"Clin Chim Acta","first-page":"55","article-title":"Homocystinuria: therapeutic approach","volume":"458","year":"2016","unstructured":"Kumar\n              T\n            , SharmaGS, SinghLR.\n          Homocystinuria: therapeutic approach. Clin Chim Acta. 2016;458:55\u201362."},{"issue":"2\u20133","key":"i1551-6776-23-6-432-b30","series-title":"J Inherit Metab Dis","first-page":"261","article-title":"Clinical approach to treatable inborn metabolic diseases: an introduction","volume":"29","year":"2006","unstructured":"Saudubray\n              JM\n            , SedelF, WalterJH.\n          Clinical approach to treatable inborn metabolic diseases: an introduction. J Inherit Metab Dis. 2006;29(2\u20133):261\u2013274."},{"issue":"1","key":"i1551-6776-23-6-432-b31","series-title":"Dev Med Child Neurol","first-page":"23","article-title":"Inborn errors of metabolism causing epilepsy","volume":"55","year":"2013","unstructured":"Rahman\n              S\n            , FootittEJ, VaradkarS, \n          et al. Inborn errors of metabolism causing epilepsy. Dev Med Child Neurol. 2013;55(1):23\u201336."},{"issue":"5","key":"i1551-6776-23-6-432-b32","series-title":"J Inherit Metab Dis","first-page":"791","article-title":"Successful pregnancy in a treated patient with biotinidase deficiency","volume":"28","year":"2005","unstructured":"Hendriksz\n              CJ\n            , PreeceMA, ChakrapaniA.\n          Successful pregnancy in a treated patient with biotinidase deficiency. J Inherit Metab Dis. 2005;28(5):791\u2013792."},{"issue":"7","key":"i1551-6776-23-6-432-b33","series-title":"N Engl J Med","first-page":"704","article-title":"Biotin treatment mimicking graves' disease","volume":"375","year":"2016","unstructured":"Kummer\n              S\n            , HermsenD, DistelmaierF.\n          Biotin treatment mimicking graves' disease. N Engl J Med. 2016;375(7):704\u2013706."},{"issue":"4","key":"i1551-6776-23-6-432-b34","series-title":"Med J Aust","first-page":"192","article-title":"A caution regarding high-dose biotin therapy: misdiagnosis of hyperthyroidism in euthyroid patients","volume":"205","year":"2016","unstructured":"Trambas\n              CM\n            , SikarisKA, LuZX.\n          A caution regarding high-dose biotin therapy: misdiagnosis of hyperthyroidism in euthyroid patients. Med J Aust. 2016;205(4):192."},{"key":"i1551-6776-23-6-432-b35","series-title":"Mitochondrion","first-page":"150","article-title":"Successful reversal of propionic acidaemia associated cardiomyopathy: evidence for low myocardial coenzyme Q10 status and secondary mitochondrial dysfunction as an underlying pathophysiological mechanism","volume":"17","year":"2014","unstructured":"Baruteau\n              J\n            , HargreavesI, KrywawychS, \n          et al. Successful reversal of propionic acidaemia associated cardiomyopathy: evidence for low myocardial coenzyme Q10 status and secondary mitochondrial dysfunction as an underlying pathophysiological mechanism. Mitochondrion. 2014;17:150\u2013156."},{"issue":"4","key":"i1551-6776-23-6-432-b36","series-title":"Neurotherapeutics","first-page":"558","article-title":"How can we treat mitochondrial encephalomyopathies?: approaches to therapy","volume":"5","year":"2008","unstructured":"Horvath\n              R\n            , GormanG, ChinneryPF.\n          How can we treat mitochondrial encephalomyopathies?: approaches to therapy. Neurotherapeutics. 2008;5(4):558\u2013568."},{"issue":"12","key":"i1551-6776-23-6-432-b37","series-title":"Mov Disord","first-page":"1924","article-title":"Safety and tolerability of high-dose coenzyme Q10 in Huntington's disease and healthy subjects","volume":"25","year":"2010","unstructured":"Hyson\n              HC\n            , KieburtzK, ShoulsonI, \n          et al. Safety and tolerability of high-dose coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord. 2010;25(12):1924\u20131928."},{"issue":"suppl","key":"i1551-6776-23-6-432-b38","series-title":"Mol Aspects Med","first-page":"s273","article-title":"Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers","volume":"15","year":"1994","unstructured":"Weis\n              M\n            , MortensenSA, RassingMR, \n          et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med. 1994;15(suppl):s273\u2013s280."},{"series-title":"Carbaglu (carglumic acid) [package insert]","key":"i1551-6776-23-6-432-b39","unstructured":"Carbaglu (carglumic acid) [package insert]. Lebanon, NJ: Recordati Rare Diseases Inc. https:\/\/www.carbaglu.net\/wp-content\/uploads\/2016\/04\/carbaglu-pi.pdf. Accessed October 19, 2018."},{"key":"i1551-6776-23-6-432-b40","series-title":"Ther Clin Risk Manag","first-page":"327","article-title":"Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency","volume":"7","year":"2011","unstructured":"Haberle\n              J.\n            \n          \n          Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther Clin Risk Manag. 2011;7:327\u2013332."},{"year":"2004","series-title":"Pediatric Drug Formulations","key":"i1551-6776-23-6-432-b41","unstructured":"Nahata\n              MC\n            , PaiVB, HippleTF.\n          Pediatric Drug Formulations. 5th ed.Cincinnati, OH: Harvey Whitney Books Co; 2004."},{"key":"i1551-6776-23-6-432-b42","series-title":"Nelson's Textbook of Pediatrics","article-title":"Methionine","year":"2011","unstructured":"Rezvani\n              I\n            , RosenblattDS.\n          Methionine. In: KliegmanRM, StantonBF, St GemeJWIII, et al, eds.Nelson's Textbook of Pediatrics. 19th ed.Philadelphia, PA: Elsevier; 2011."},{"issue":"7953","key":"i1551-6776-23-6-432-b43","series-title":"Lancet","first-page":"256","article-title":"Pyridoxine and serum concentration of phenytoin and phenobarbitone","volume":"1","year":"1976","unstructured":"Hansson\n              O\n            , SillanpaaM.\n          Pyridoxine and serum concentration of phenytoin and phenobarbitone. Lancet. 1976;1(7953):256."},{"issue":"2","key":"i1551-6776-23-6-432-b44","series-title":"Arch Neurol","first-page":"181","article-title":"Subnormal serum folate due to anticonvulsive therapy: a double-blind study of the effect of folic acid treatment in patients with drug-induced subnormal serum folates","volume":"22","year":"1970","unstructured":"Jensen\n              ON\n            , OlesenOV.\n          Subnormal serum folate due to anticonvulsive therapy: a double-blind study of the effect of folic acid treatment in patients with drug-induced subnormal serum folates. Arch Neurol. 1970;22(2):181\u2013182."},{"issue":"2","key":"i1551-6776-23-6-432-b45","series-title":"Am J Med Genet","first-page":"195","article-title":"Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy","volume":"111","year":"2002","unstructured":"Van Hove\n              JL\n            , Van Damme-LombaertsR, Gr\u00fcnewaldS, \n          et al. Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. Am J Med Genet. 2002;111(2):195\u2013201."},{"issue":"6","key":"i1551-6776-23-6-432-b46","series-title":"J Inherit Metab Dis","first-page":"728","article-title":"Hydroxocobalamin dose escalation improves metabolic control in cblC","volume":"32","year":"2009","unstructured":"Carrillo-Carrasco\n              N\n            , SloanJ, ValleD, \n          et al. Hydroxocobalamin dose escalation improves metabolic control in cblC. J Inherit Metab Dis. 2009;32(6):728\u2013731."},{"key":"i1551-6776-23-6-432-b47","series-title":"Mol Genet Metab Rep","first-page":"48","article-title":"Tyrosinemia type III in an asymptomatic girl","volume":"5","year":"2015","unstructured":"Szymanska\n              E\n            , SredzinskaM, CiaraE, \n          et al. Tyrosinemia type III in an asymptomatic girl. Mol Genet Metab Rep. 2015;5:48\u201350."},{"issue":"suppl 1","key":"i1551-6776-23-6-432-b48","series-title":"Clin Toxicol (Phila)","first-page":"17","article-title":"Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study","volume":"44","year":"2006","unstructured":"Uhl\n              W\n            , NoltingA, GolorG, \n          et al. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila). 2006;44(suppl 1):17\u201328."},{"issue":"1","key":"i1551-6776-23-6-432-b49","series-title":"Pediatr Cardiol","first-page":"163","article-title":"Carnitine membrane transporter deficiency: a rare treatable cause of cardiomyopathy and anemia","volume":"29","year":"2008","unstructured":"Cano\n              A\n            , OvaertC, Vianey-SabanC, \n          et al. Carnitine membrane transporter deficiency: a rare treatable cause of cardiomyopathy and anemia. Pediatr Cardiol. 2008;29(1):163\u2013165."},{"issue":"7\u20138","key":"i1551-6776-23-6-432-b50","series-title":"Ann Pharmacother","first-page":"1287","article-title":"L-carnitine for acute valproic acid overdose: a systematic review of published cases","volume":"44","year":"2010","unstructured":"Perrott\n              J\n            , MurphyNG, ZedPJ.\n          L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother. 2010;44(7\u20138):1287\u20131293."},{"issue":"4","key":"i1551-6776-23-6-432-b51","series-title":"Am J Kidney Dis","first-page":"868","article-title":"Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder: National Kidney Foundation carnitine consensus conference","volume":"41","year":"2003","unstructured":"Eknoyan\n              G\n            , LatosDL, LindbergJ.\n          Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder: National Kidney Foundation carnitine consensus conference. Am J Kidney Dis. 2003; 41(4):868\u2013876."},{"issue":"2","key":"i1551-6776-23-6-432-b52","series-title":"Pediatr Int","first-page":"281","article-title":"Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience","volume":"57","year":"2015","unstructured":"Zeybek\n              AC\n            , KiykimE, SoyucenE, \n          et al. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience. Pediatr Int. 2015;57(2):281\u2013289."},{"issue":"2","key":"i1551-6776-23-6-432-b53","series-title":"J Pediatr","first-page":"398","article-title":"Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone","volume":"164","year":"2014","unstructured":"Bendadi\n              F\n            , de KoningTJ, VisserG, \n          et al. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone. J Pediatr. 2014;164(2):398\u2013401."},{"key":"i1551-6776-23-6-432-b54","series-title":"Orphanet J Rare Dis","first-page":"107","article-title":"Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice","volume":"9","year":"2014","unstructured":"Mayorandan\n              S\n            , MeyerU, GokcayG, \n          et al. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis. 2014;9:107."},{"issue":"2","key":"i1551-6776-23-6-432-b55","series-title":"J Inherit Metab Dis","first-page":"263","article-title":"Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC","volume":"35","year":"2012","unstructured":"Thimm\n              E\n            , Richter-WerkleR, KampG, \n          et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis. 2012;35(2):263\u2013268."},{"year":"2016","series-title":"Orfandin (nitisinone) [package insert]","key":"i1551-6776-23-6-432-b56","unstructured":"Orfandin (nitisinone) [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; 2016. https:\/\/sobi-northamerica.com\/sites\/sobi-northamerica.com\/files\/2018-06\/Canada.Orfadin_PM_EN.pdf Accessed October 19, 2018."},{"issue":"14","key":"i1551-6776-23-6-432-b57","series-title":"Am J Health Syst Pharm","first-page":"1513","article-title":"Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions","volume":"64","year":"2007","unstructured":"Caruthers\n              RL\n            , JohnsonCE.\n          Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions. Am J Health Syst Pharm. 2007;64(14):1513\u20131515."},{"year":"2017","series-title":"Ravicti (glycerol phenylbutyrate) [package insert]","key":"i1551-6776-23-6-432-b58","unstructured":"Ravicti (glycerol phenylbutyrate) [package insert]. Lake Forest, IL: Horizon Therapeutics; 2017. https:\/\/hznp.azureedge.net\/public\/ravicti_1-1g-ml_vial_pi_effective_us.PDF. Accessed October 19, 2018."},{"issue":"1","key":"i1551-6776-23-6-432-b59","series-title":"Mol Genet Metab","first-page":"17","article-title":"Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes","volume":"112","year":"2014","unstructured":"Berry\n              SA\n            , Lichter-KoneckiU, DiazGA, \n          et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes. Mol Genet Metab. 2014;112(1):17\u201324."},{"issue":"5","key":"i1551-6776-23-6-432-b60","series-title":"Can J Hosp Pharm","first-page":"394","article-title":"Stability of extemporaneously compounded pyridoxine in glass and plastic bottles and plastic syringes","volume":"67","year":"2014","unstructured":"Ensom\n              MH\n            , DecarieD.\n          Stability of extemporaneously compounded pyridoxine in glass and plastic bottles and plastic syringes. Can J Hosp Pharm. 2014;67(5):394\u2013396."},{"issue":"1\u20132","key":"i1551-6776-23-6-432-b61","series-title":"Mol Genet Metab","first-page":"48","article-title":"Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment, and follow-up","volume":"104","year":"2011","unstructured":"Stockler\n              S\n            , PleckoB, GospeSMJr, \n          et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment, and follow-up. Mol Genet Metab. 2011;104(1\u20132):48\u201360."},{"issue":"4","key":"i1551-6776-23-6-432-b62","series-title":"Int J Pharm Compd","first-page":"343","article-title":"Riboflavin 5 mg\/mL oral suspension","volume":"15","year":"2011","unstructured":"Allen, Loyd VJr.\n          \n          Riboflavin 5 mg\/mL oral suspension. Int J Pharm Compd. 2011;15(4):343."},{"issue":"5","key":"i1551-6776-23-6-432-b63","series-title":"Ann Allergy Asthma Immunol","first-page":"430","article-title":"Anaphylaxis to riboflavin (vitamin B2)","volume":"87","year":"2001","unstructured":"Ou\n              LS\n            , KuoML, HuangJL.\n          Anaphylaxis to riboflavin (vitamin B2). Ann Allergy Asthma Immunol. 2001;87(5):430\u2013433."},{"issue":"2","key":"i1551-6776-23-6-432-b64","series-title":"Genet Med","first-page":"188","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","year":"2014","unstructured":"Vockley\n              J\n            , AnderssonHC, AntshelKM, \n          et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188\u2013200."},{"issue":"4","key":"i1551-6776-23-6-432-b65","series-title":"Mol Genet Metab","first-page":"557","article-title":"Long-term safety and efficacy of sapropterin: the PKUDOS registry experience","volume":"114","year":"2015","unstructured":"Longo\n              N\n            , ArnoldGL, PridjianG, \n          et al. Long-term safety and efficacy of sapropterin: the PKUDOS registry experience. Mol Genet Metab. 2015;114(4):557\u2013563."},{"issue":"3","key":"i1551-6776-23-6-432-b66","series-title":"Cochrane Database Syst Rev","article-title":"Sapropterin dihydrochloride for phenylketonuria","year":"2015","unstructured":"Somaraju\n              UR\n            , MerrinM.\n          Sapropterin dihydrochloride for phenylketonuria. Cochrane Database Syst Rev. 2015;(3):DC008005."},{"key":"i1551-6776-23-6-432-b67","series-title":"Can J Hosp Pharm","first-page":"26","article-title":"Stability of thiamine in extemporaneously compounded suspensions","volume":"58","year":"2005","unstructured":"Ensom\n              MHH\n            , DecarieD.\n          Stability of thiamine in extemporaneously compounded suspensions. Can J Hosp Pharm. 2005;58:26\u201330."},{"issue":"9","key":"i1551-6776-23-6-432-b68","series-title":"Clin Pediatr (Phila)","first-page":"519","article-title":"Pyruvate carboxylase deficiency: report of a case and additional evidence for the \u201cmild\u201d phenotype","volume":"40","year":"2001","unstructured":"Arnold\n              GL\n            , GriebelML, PorterfieldM, \n          et al. Pyruvate carboxylase deficiency: report of a case and additional evidence for the \u201cmild\u201d phenotype. Clin Pediatr (Phila). 2001;40(9):519\u2013521."},{"issue":"5","key":"i1551-6776-23-6-432-b69","series-title":"Best Pract Res Clin Gastroenterol","first-page":"607","article-title":"Inborn errors of carbohydrate metabolism","volume":"24","year":"2010","unstructured":"Mayatepek\n              E\n            , HoffmannB, MeissnerT.\n          Inborn errors of carbohydrate metabolism. Best Pract Res Clin Gastroenterol. 2010;24(5):607\u2013618."},{"issue":"2","key":"i1551-6776-23-6-432-b70","series-title":"Arg Neuropsiquiatr","first-page":"166","article-title":"Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease","volume":"74","year":"2016","unstructured":"Llerena Junior\n              JC\n            , NascimentoOJ, OliveiraAS, \n          et al. Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease. Arg Neuropsiquiatr. 2016;74(2):166\u2013176."},{"issue":"6","key":"i1551-6776-23-6-432-b71","series-title":"Pediatrics","first-page":"E69","article-title":"Inborn errors of metabolism in infancy: a guide to diagnosis","volume":"102","year":"1998","unstructured":"Burton\n              BK.\n            \n          \n          Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics. 1998;102(6):E69."},{"issue":"4","key":"i1551-6776-23-6-432-b72","series-title":"J Neurol","first-page":"621","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","year":"2017","unstructured":"Schoser\n              B\n            , StewartA, KantersS, \n          et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621\u2013630."},{"issue":"4","key":"i1551-6776-23-6-432-b73","series-title":"Pediatr Rev","first-page":"e22","article-title":"Inborn errors of metabolism: part 2: specific disorders","volume":"30","year":"2009","unstructured":"Levy\n              PA.\n            \n          \n          Inborn errors of metabolism: part 2: specific disorders. Pediatr Rev. 2009;30(4):e22\u2013e28."},{"issue":"18","key":"i1551-6776-23-6-432-b74","series-title":"Intern Med","first-page":"2659","article-title":"First Japanese case of carnitine palmitoyltransferase II deficiency with the homozygous point mutation S113L","volume":"55","year":"2016","unstructured":"Shima\n              A\n            , YasunoT, YamadaK, \n          et al. First Japanese case of carnitine palmitoyltransferase II deficiency with the homozygous point mutation S113L. Intern Med. 2016;55(18):2659\u20132661."},{"issue":"1","key":"i1551-6776-23-6-432-b75","series-title":"J Inherit Metab Dis","first-page":"115","article-title":"Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians","volume":"35","year":"2012","unstructured":"Potter\n              BK\n            , LittleJ, ChakrabortyP, \n          et al. Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians. J Inherit Metab Dis. 2012;35(1):115\u2013123."},{"key":"i1551-6776-23-6-432-b76","series-title":"Orphanet J Rare Dis","first-page":"102","article-title":"Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency","volume":"8","year":"2013","unstructured":"Couce\n              ML\n            , S\u00e1nchez-PintosP, DiogoL, \n          et al. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: regional experience and high incidence of carnitine deficiency. Orphanet J Rare Dis. 2013;8:102."},{"issue":"2","key":"i1551-6776-23-6-432-b77","series-title":"Ann Neurol","first-page":"279","article-title":"Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency","volume":"56","year":"2004","unstructured":"\u00d8Rngreen\n              MC\n            , N\u00f8rgaardMG, SacchettiM, \n          et al. Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Ann Neurol. 2004;56(2):279\u2013283."},{"issue":"1","key":"i1551-6776-23-6-432-b78","series-title":"Hum Genet","first-page":"43","article-title":"The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level","volume":"124","year":"2008","unstructured":"Pedersen\n              CB\n            , K\u00f8lvraaS, K\u00f8lvraaA, \n          et al. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum Genet. 2008;124(1):43\u201356."},{"key":"i1551-6776-23-6-432-b79","series-title":"Nelson's Textbook of Pediatrics","article-title":"Valine, leucine, isoleucine, and related organic acidemias","year":"2011","unstructured":"Rezvani\n              I\n            , RosenblattDS.\n          Valine, leucine, isoleucine, and related organic acidemias. In: KliegmanRM, StantonBF, St GemeJWIII, et al, eds.Nelson's Textbook of Pediatrics. 19th ed.Philadelphia, PA: Elsevier; 2011."},{"issue":"1","key":"i1551-6776-23-6-432-b80","series-title":"Mol Genet Metab","first-page":"16","article-title":"Acute management of propionic academia","volume":"105","year":"2012","unstructured":"Chapman\n              KA\n            , GropmanA, MacleodE, \n          et al. Acute management of propionic academia. Mol Genet Metab. 2012;105(1):16\u201325."},{"issue":"1","key":"i1551-6776-23-6-432-b81","series-title":"Cell Mol Neurobiol","first-page":"77","article-title":"Oxidative stress parameters in urine from patients with disorders of propionate metabolism: a beneficial effect of L-carnitine supplementation","volume":"32","year":"2012","unstructured":"Ribas\n              GS\n            , BianciniGB, MesckaC, \n          et al. Oxidative stress parameters in urine from patients with disorders of propionate metabolism: a beneficial effect of L-carnitine supplementation. Cell Mol Neurobiol. 2012;32(1):77\u201382."},{"key":"i1551-6776-23-6-432-b82","series-title":"Orphanet J Rare Dis","first-page":"130","article-title":"Proposed guidelines for the diagnosis and management of methyl-malonic and propionic academia","volume":"9","year":"2014","unstructured":"Baumgartner\n              MR\n            , H\u00f6rsterF, Dionisi-ViciC, \n          et al. Proposed guidelines for the diagnosis and management of methyl-malonic and propionic academia. Orphanet J Rare Dis. 2014;9:130."},{"issue":"6281","key":"i1551-6776-23-6-432-b83","series-title":"Science","first-page":"54","article-title":"Hypoxia as a therapy for mitochondrial disease","volume":"352","year":"2016","unstructured":"Jain\n              IH\n            , ZazzeronL, GoliR, \n          et al. Hypoxia as a therapy for mitochondrial disease. Science. 2016;352(6281):54\u201361."},{"issue":"10","key":"i1551-6776-23-6-432-b84","series-title":"J Child Neurol","first-page":"NP105","article-title":"Long survival in patients with Leigh syndrome and the m.10191T>C mutation in MT-ND3: a case report and review of the literature","volume":"29","year":"2014","unstructured":"Levy\n              RJ\n            , RiosPG, AkmanHO, \n          et al. Long survival in patients with Leigh syndrome and the m.10191T>C mutation in MT-ND3: a case report and review of the literature. J Child Neurol. 2014:29(10):NP105\u2013NP110."},{"issue":"2","key":"i1551-6776-23-6-432-b85","series-title":"J Neuroimaging","first-page":"e117","article-title":"Inborn errors of metabolism presenting in childhood","volume":"21","year":"2011","unstructured":"Cakir\n              B\n            , TeksamM, KosehanD, \n          et al. Inborn errors of metabolism presenting in childhood. J Neuroimaging. 2011;21(2):e117\u2013e133."},{"issue":"3","key":"i1551-6776-23-6-432-b86","series-title":"J Neurol Neurosurg Psychiatry","first-page":"257","article-title":"A guide to diagnosis and treatment of Leigh syndrome","volume":"85","year":"2014","unstructured":"Baertling\n              F\n            , RodenburgRJ, SchaperJ, \n          et al. A guide to diagnosis and treatment of Leigh syndrome. J Neurol Neurosurg Psychiatry. 2014;85(3):257\u2013265."},{"issue":"21","key":"i1551-6776-23-6-432-b87","series-title":"Intern Med","first-page":"2663","article-title":"A case of late onset riboflavin-responsive multiple acyl-coa dehydrogenase deficiency manifesting as recurrent rhabdomyolysis and acute renal failure","volume":"50","year":"2011","unstructured":"Izumi\n              R\n            , SuzukiN, NagataM, \n          et al. A case of late onset riboflavin-responsive multiple acyl-coa dehydrogenase deficiency manifesting as recurrent rhabdomyolysis and acute renal failure. Intern Med. 2011;50(21):2663\u20132668."},{"issue":"6","key":"i1551-6776-23-6-432-b88","series-title":"Am J Hum Genet","first-page":"1130","article-title":"Riboflavin-responsive and \u2013non-responsive mutations in FAD synthase cause multiple acyl-coa dehydrogenase and combined respiratory-chain deficiency","volume":"98","year":"2016","unstructured":"Olsen\n              RK\n            , Ko\u0148a\u0159\u00edkov\u00e1E, GiancasperoTA, \n          et al. Riboflavin-responsive and \u2013non-responsive mutations in FAD synthase cause multiple acyl-coa dehydrogenase and combined respiratory-chain deficiency. Am J Hum Genet. 2016;98(6):1130\u20131145."},{"key":"i1551-6776-23-6-432-b89","series-title":"Nelson's Textbook of Pediatrics","article-title":"Defects in metabolism of lipids","year":"2011","unstructured":"Stanley\n              CA\n            , BennettMJ.\n          Defects in metabolism of lipids. In: KliegmanRM, StantonBF, St GemeJWIII, et al, eds.Nelson's Textbook of Pediatrics. 19th ed.Philadelphia, PA: Elsevier; 2011."},{"issue":"6","key":"i1551-6776-23-6-432-b90","series-title":"Acta Paediatr","first-page":"953","article-title":"Sapropterin treatment does not enhance the health-related quality of life of patients with phenylketonuria and their parents","volume":"106","year":"2017","unstructured":"Feldmann\n              R\n            , WolfgartE, WeglageJ, RutschF.\n          Sapropterin treatment does not enhance the health-related quality of life of patients with phenylketonuria and their parents. Acta Paediatr. 2017;106(6):953\u2013959."},{"key":"i1551-6776-23-6-432-b91","series-title":"Nelson's Textbook of Pediatrics","article-title":"Phenylalanine","year":"2011","unstructured":"Rezvani\n              I\n            , MelvinJJ.\n          Phenylalanine. In: KliegmanRM, StantonBF, St GemeJWIII, et al, eds.Nelson's Textbook of Pediatrics. 19th ed.Philadelphia, PA: Elsevier; 2011."},{"issue":"6","key":"i1551-6776-23-6-432-b92","series-title":"Proc Natl Acad Sci U S A","first-page":"3160","article-title":"A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients","volume":"96","year":"1999","unstructured":"Kaufman\n              S.\n            \n          \n          A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients. Proc Natl Acad Sci U S A. 1999;96(6):3160\u20133164."},{"issue":"4","key":"i1551-6776-23-6-432-b93","series-title":"PLoS One","first-page":"e19030","article-title":"Efficient conversion of phenylpyruvic acid to phenyllactic acid by using whole cells of bacillus coagulans SDM","volume":"6","year":"2011","unstructured":"Zheng\n              Z\n            , MaC, GaoC\n          et al. Efficient conversion of phenylpyruvic acid to phenyllactic acid by using whole cells of bacillus coagulans SDM. PLoS One. 2011;6(4):e19030."},{"issue":"2","key":"i1551-6776-23-6-432-b94","series-title":"J Inherit Metab Dis","first-page":"391","article-title":"Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of life","volume":"34","year":"2011","unstructured":"ten Hoedt\n              AE\n            , Maurice-StamH, BoelenCC, \n          et al. Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of life. J Inherit Metab Dis. 2011;34(2):391\u2013398."},{"issue":"1","key":"i1551-6776-23-6-432-b95","series-title":"Clin Chem Lab Med","first-page":"157","article-title":"Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry","volume":"51","year":"2013","unstructured":"Ozben\n              T.\n            \n          \n          Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry. Clin Chem Lab Med. 2013;51(1):157\u2013176."},{"issue":"8","key":"i1551-6776-23-6-432-b96","series-title":"Arch Dis Child","first-page":"738","article-title":"Outcome of children with hereditary tyrosinaemia following newborn screening","volume":"100","year":"2015","unstructured":"McKiernan\n              PJ\n            , PreeceMA, ChakrapaniA.\n          Outcome of children with hereditary tyrosinaemia following newborn screening. Arch Dis Child. 2015;100(8):738\u2013741."},{"key":"i1551-6776-23-6-432-b97","series-title":"Nelson's Textbook of Pediatrics","article-title":"Tyrosine","year":"2011","unstructured":"Mitchell\n              GA\n            , RezvaniI.\n          Tyrosine. In: KliegmanRM, StantonBF, St GemeJWIII, et al, eds.Nelson's Textbook of Pediatrics. 19th ed.Philadelphia, PA: Elsevier; 2011."},{"issue":"4","key":"i1551-6776-23-6-432-b98","series-title":"Eur J Paediatr Neurol","first-page":"674","article-title":"An unfortunate challenge: ketogenic diet for the treatment of lennox-gastaut syndrome in tyrosinemia type 1","volume":"20","year":"2016","unstructured":"De Lucia\n              S\n            , PichardS, IleaA, \n          et al. An unfortunate challenge: ketogenic diet for the treatment of lennox-gastaut syndrome in tyrosinemia type 1. Eur J Paediatr Neurol. 2016;20(4):674\u2013677."},{"issue":"10","key":"i1551-6776-23-6-432-b99","series-title":"Cornea","first-page":"1106","article-title":"In vivo confocal microscopic features of cornealpseudodendritic lesions in tyrosinemia type II","volume":"33","year":"2014","unstructured":"Kocabeyoglu\n              S\n            , MocanMC, IrkecM.\n          In vivo confocal microscopic features of cornealpseudodendritic lesions in tyrosinemia type II. Cornea. 2014;33(10):1106\u20131108."},{"issue":"1","key":"i1551-6776-23-6-432-b100","series-title":"J Inherit Metab Dis","first-page":"103","article-title":"Combined methylmalonic acidemia and homocystinuria, cblC type. II: complications, pathophysiology, and outcomes","volume":"35","year":"2012","unstructured":"Carillo-Carrasco\n              N\n            , VendittiCP.\n          Combined methylmalonic acidemia and homocystinuria, cblC type. II: complications, pathophysiology, and outcomes. J Inherit Metab Dis. 2012;35(1):103\u2013114."},{"issue":"3","key":"i1551-6776-23-6-432-b101","series-title":"Neurology","first-page":"e41","article-title":"Pearls & oysters: familial epileptic encephalopathy due to methylenetetrahydrofolate reductase deficiency","volume":"83","year":"2014","unstructured":"Cappuccio\n              G\n            , CozzolinoC, FrissoG, \n          et al. Pearls & oysters: familial epileptic encephalopathy due to methylenetetrahydrofolate reductase deficiency. Neurology. 2014;83(3):e41\u2013e44."},{"key":"i1551-6776-23-6-432-b102","series-title":"Orphanet J Rare Dis","first-page":"73","article-title":"Brain-blood amino acid correlates following protein restriction in murine maple syrup urine disease","volume":"9","year":"2014","unstructured":"Vogel, KR, ArningE, WasekBL, \n          et al. Brain-blood amino acid correlates following protein restriction in murine maple syrup urine disease. Orphanet J Rare Dis. 2014;9:73."},{"issue":"3","key":"i1551-6776-23-6-432-b103","series-title":"Mol Genet Metab","first-page":"210","article-title":"Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach","volume":"112","year":"2014","unstructured":"Frazier\n              DM\n            , AllgeierC, HomerC, \n          et al. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metab. 2014;112(3):210\u2013217."},{"issue":"26","key":"i1551-6776-23-6-432-b104","series-title":"Medicine (Baltimore)","first-page":"e7365","article-title":"Neonatal-onset carbamoyl phosphate synthetase I deficiency: a case report","volume":"96","year":"2017","unstructured":"Yang\n              X\n            , ShiJ, LeiH, \n          et al. Neonatal-onset carbamoyl phosphate synthetase I deficiency: a case report: Medicine (Baltimore). 2017;96(26):e7365."},{"issue":"1","key":"i1551-6776-23-6-432-b105","series-title":"Pediatr Int","first-page":"e1","article-title":"Early intervention for late-onset ornithine transcarbamylase deficiency","volume":"57","year":"2015","unstructured":"Fujisawa\n              D\n            , MitsubuchiH, MatsumotoS, \n          et al. Early intervention for late-onset ornithine transcarbamylase deficiency. Pediatr Int. 2015;57(1):e1\u2013e3."},{"issue":"1","key":"i1551-6776-23-6-432-b106","series-title":"J Inherit Metab Dis","first-page":"21","article-title":"Cross-sectional observational study of 208 patients with non-classical urea cycle disorders","volume":"37","year":"2014","unstructured":"R\u016begger\n              CM\n            , LindnerM, BallhausenD, \n          et al. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. J Inherit Metab Dis. 2014;37(1):21\u201330."},{"issue":"4","key":"i1551-6776-23-6-432-b107","series-title":"Pediatr Neurol","first-page":"263","article-title":"Arginase deficiency with new phenotype and a novel mutation: contemporary summary","volume":"47","year":"2012","unstructured":"Tsang\n              JP\n            , PoonWL, LukHM, \n          et al. Arginase deficiency with new phenotype and a novel mutation: contemporary summary. Pediatr Neurol. 2012;47(4):263\u2013269."},{"issue":"5","key":"i1551-6776-23-6-432-b108","series-title":"Ann Hepatol","first-page":"803","article-title":"Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine","volume":"12","year":"2013","unstructured":"Jiang\n              Q\n            , JiangG, ShiKQ, \n          et al. Oral acetyl-L-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine. Ann Hepatol. 2013;12(5):803\u2013809."},{"issue":"1\u20132","key":"i1551-6776-23-6-432-b109","series-title":"Mol Genet Metab","first-page":"127","article-title":"A longitudinal study of urea cycle disorders","volume":"113","year":"2014","unstructured":"Batshaw\n              ML\n            , TuchmanM, SummarM, \n          et al. A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014;113(1\u20132):127\u2013130."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/23\/6\/article-p432.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/23\/6\/432\/1785546\/1551-6776-23_6_432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/23\/6\/article-p432.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/23\/6\/article-p432.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:35:36Z","timestamp":1747355736000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/23\/6\/article-p432.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":109,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-23.6.432","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2018]]}}}